Theratechnologies Inc T.TH

Aasld

[qwerty22]

Thought this was a good summary of the highlights of aasld so sharing. Crazy how Loomba is at the center of so much.
https://www.hepmag.com/article/pipeline-nafld-nash-treatment

This one is super intriguing given tesamorelin's history. I don't expect it changes any paradigms but maybe it's something to think about when Ph4s roll around.
https://www.newswise.com/articles/high-abdominal-fat-and-low-liver-fat-combo-increases-coronary-heart-disease-risk
It is intriguing maybe given some of the secondary measurements THTX might make during the Ph3. It strikes me that mdgl see what their drug is capable of and then shift the discussion towards that. Thtx could think about doing something similar.

[SPCEO1]

I think I have mentioned it before but my uneducated view is that, in the end, Egrifta will be shown to be useful in many other ways than just helping with NASH and CV benefits are at the top of my list for additional benefits. We are a long way from knowing anything about that, however, but it just makes sense to me that this will be the case. 

[qwerty22]

At some point eventually big pharma will buy all the leading Nash drug you'd expect. And ultimately what matters is the ability of these drugs to impact not just surrogate endpoints but the long term endpoints like end stage liver diseases and CV events. Pharma bucks will be purchasing drugs on what they can show about those long term outcomes because that's what gives the drug a long life

[SPCEO1]

This is one of the problems with the low share price. We know there is a good chance things could turn out to be very, very, very interesting in both cancer and NASH, but that view has not been broadly accepted. The resulting low share price means the company has been cash poor (relative to most successful US biotech stocks) and that likely means there is a reluctance to spend on anything extra. I

[Wino115]

I think both company and any interested partner would only move after results which would show promise, thus move the share a bunch higher.  We'll get some kind of read on cancer in 2021 as survival or tumor fighting capacity would have to be released one way or the other and something in 2022 on NASH.  Between here and there, it should be clear to them if the cheapest financing is

[qwerty22]

What? A measly $100 mil would make all the difference? I'm sure you've got that lying around! If not you then Reality :)

[realitycheck4u]

This post has been removed in accordance with Community Policy

[Bucknelly21]

We should have much clarity in 2021 and be quite happy 

[realitycheck4u]

This post has been removed in accordance with Community Policy

[palinc2000]

My uneducated dream is that Egrifta evolves in Nash and oher indications as Keytruda evolved and is still evolving in cancer  indications. This is the Mother of all dreams!!!! Am still very much tied up in an another matter  but still have the opportunity to dream !!!